多参数定量弥散加权磁共振成像可有效预测交界可切除胰腺导管腺癌新辅助治疗反应
该研究分析72例交界可切除胰腺导管腺癌患者的临床病理数据及DWI参数(ADC、D、f值),比较新辅助治疗前后差异。治疗后反应组ADC和D值显著高于无反应组,f值更低;ΔADC(OR:12.24,P=0.013)是肿瘤反应的最重要独立因素,AUC为0.936。高ADC值组、高D值组和低f值组与新辅助治疗后更好预后相关;ΔADC≥0组、ΔD≥0组和Δf<0组与更好预后显著相关。亚组分析提示两组患者可能从新辅助治疗中获益。
要点
- 治疗后反应组ADC和D值显著高于无反应组,f值更低。
- ΔADC是肿瘤反应最重要独立因素(OR:12.24,P=0.013),AUC为0.936。
- 高ADC值组、高D值组、低f值组及ΔADC≥0组、ΔD≥0组、Δf<0组与更好预后相关。
核心结论
- 多参数定量DWI可能为交界可切除胰腺导管腺癌新辅助治疗的疗效和预后提供有价值的信息,这些发现有可能支持接受新辅助治疗患者的评估和决策过程。
研究设计与样本
- 研究纳入72例交界可切除胰腺导管腺癌患者,分析其临床病理数据(包括肿瘤大小、位置和CA19-9值)及DWI参数(ADC、D和f值),比较新辅助治疗前后这些因素的差异和变化,采用ROC分析评估诊断效能,Kaplan-Meier生存分析探讨DWI参数与预后的关系,并进行亚组生存分析。
诊断标准与关键数值
- ΔADC预测新辅助治疗反应的AUC为0.936;ΔADC作为独立因素的OR为12.24(P=0.013)。
临床应用与阅片要点
- 原文结论指出多参数定量DWI可能为交界可切除胰腺导管腺癌新辅助治疗的疗效和预后提供有价值的信息,并有可能支持患者的评估和决策过程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate whether multiparametric quantitative diffusion weighted magnetic resonance imaging (DWI) can effectively predict the neoadjuvant therapy (NAT) response in borderline resectable pancreatic ductal adenocarcinoma (BRPC).
METHODS: The clinicopathological data, including tumor size, location, and CA19-9 values, as well as DWI parameters(ADC, D, and f values) from 72 patients with BRPC, were analyzed. The differences and changes in these factors before and after NAT were compared to identify those most accurately reflect the response to NAT. ROC analysis was used to evaluate the diagnostic efficacy, and Kaplan-Meier survival analysis explored the relationship between DWI parameters and prognosis. Subgroup survival analysis to further identify populations potentially benefiting from NAT based on multiparametric DWI.
RESULTS: After-NAT, the response group showed significantly higher ADC and D values and lower f values compared to the non-response group. The ΔADC (OR: 12.24, P = 0.013) emerged as the most important independent factor for tumor response, demonstrating the highest diagnostic accuracy for NAT response with an AUC of 0.936. Kaplan-Meier showed the high ADC value group, high D value group and low f value group were associated with better prognosis after NAT; and the ΔADC ≥ 0 group, ΔD ≥ 0 group, and Δf < 0 group was significantly associated with better prognosis. In addition, subgroup analysis suggested two groups of patients might potentially benefit from NAT.
CONCLUSIONS: Multiparametric quantitative DWI may offer valuable insights into the efficacy and prognosis of NAT in BRPC. These findings have the potential to support the evaluation and decision-making process for patients undergoing NAT.
引用
- Qu C, Zeng P, Hu W, et al. Multiparametric quantitative diffusion weighted magnetic resonance imaging can effectively predict the response to neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma. Eur J Radiol. 2024. PMID: 39753006. doi:10.1016/j.ejrad.2024.111893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。